Catalyst

Slingshot members are tracking this event:

Phase 2 study of GI-6301 treatment on patients with Chordoma expected to complete March 2019 - Acquired by NantCell, Inc.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GBIM

100%

Additional Information

Additional Relevant Details Initially, The Phase 2 study by GlobalImmune of its drug GI-6301 on patients with chordoma with radiation treatment is expected to reach primary completion date in March 2017.  The study's primary endpoint is to measure the "difference in overall response rate among patients with Chordoma who are treated with radiation plus placebo vs. radiation plus vaccine."

It is now expected in March 2019.
https://www.clinical...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Study, Gi-6301, Chordoma